Recombinant feline herpesvirus-1 (FHV-1) expressing granulocyte colony-stimulating factor (G-CSF) exhibits enhanced protective efficacy in felines

Vaccine efficacy relies not only on antigens but also on immunomodulatory agents/adjuvants that are often used to stimulate the immune system and enhance the immune response. However, current immunomodulatory agents are used to increase the immune response induced by viral or bacterial inactivated vaccine antigens, bacterial toxoids or polysaccharides but not attenuated live viruses. Based on the immunomodulatory functions of G-CSF and the characteristics of feline herpesvirus-1 (FHV-1) as an expression vector, a recombinant virus expressing feline G-CSF (WH2020-ΔTK/gI/gE-G-CSF) was constructed. The growth dynamics of WH2020-ΔTK/gI/gE-G-CSF were similar to those of WH2020-ΔTK/gI/gE. Compared with kittens vaccinated with WH2020 Δ TK/gI/gE, felines inoculated with WH2020 ΔTK/gI/gE-G-CSF produced more neutralizing antibodies and neutrophils, further alleviating clinical symptoms after FHV-1 infection. Taken together, our results revealed the potential of G-CSF as an ideal immune potentiator that can augment immune responses to FHV-1 and even other attenuated live vaccines. •We first generated a novel FHV-1 recombinant WH2020-ΔTK/gI/gE-G-CSF with TK/gI/gE gene deletion and Felis catus G-CSF protein co-expression.•WH2020-ΔTK/gI/gE-G-CSF displayed high safety in kittens after intranasally challenge.•WH2020-ΔTK/gI/gE-G-CSF provided great protection against virulent FHV-1 challenge.